European companies aren't alone in their Brexit pain. Pfizer Inc., the U.S.-based drug behemoth, says its costs for dealing with the upcoming split will reach $100 million.

The U.K.'s looming rupture with the European Union (EU) threatens to slow goods at borders that are now wide open and force companies to duplicate regulatory efforts. Pfizer said in an email that its costs stem from transferring product testing and licenses to other countries, changing clinical-trial management procedures, and other preventive measures.

The company is working “to meet EU legal requirements after the U.K. is no longer a member state, especially in the regulatory, manufacturing, and supply-chain areas,” according to a filing last month where it cited the cost estimate.

Continue Reading for Free

Register and gain access to:

  • Thought leadership on regulatory changes, economic trends, corporate success stories, and tactical solutions for treasurers, CFOs, risk managers, controllers, and other finance professionals
  • Informative weekly newsletter featuring news, analysis, real-world case studies, and other critical content
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical coverage of the employee benefits and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.